Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen
<p>Abstract</p> <p>Background</p> <p>Pharmacological high-throughput screening (HTS) represents a powerful strategy for drug discovery in genetic diseases, particularly when the full spectrum of pathological dysfunctions remains unclear, such as in Friedreich ataxia (FR...
Main Authors: | Haiech Jacques, Hibert Marcel, Reutenauer Laurence, Villa Pascal, Seznec Hervé, Calmels Nadège, Rustin Pierre, Koenig Michel, Puccio Hélène |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2009-08-01
|
Series: | BMC Neurology |
Online Access: | http://www.biomedcentral.com/1471-2377/9/46 |
Similar Items
-
The first cellular models based on frataxin missense mutations that reproduce spontaneously the defects associated with Friedreich ataxia.
by: Nadège Calmels, et al.
Published: (2009-07-01) -
Friedreich's Ataxia, Frataxin, PIP5K1B: Echo of a Distant Fracas
by: Aurélien Bayot, et al.
Published: (2013-01-01) -
Neurodegeneration in Friedreich’s Ataxia: From Defective Frataxin to Oxidative Stress
by: Cláudio M. Gomes, et al.
Published: (2013-01-01) -
Novel frataxin isoforms may contribute to the pathological mechanism of Friedreich ataxia.
by: Haiyan Xia, et al.
Published: (2012-01-01) -
HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model.
by: Myriam Rai, et al.
Published: (2008-01-01)